Post Profile

Mylan to pay $465 million over Medicaid pricing of EpiPen

Mylan will pay the Department of Justice $465 million in a settlement over its pricing and classification of the EpiPen through Medicaid, the pharmaceutical company announced Friday.  Mylan, which came under fire this summer for systematically hiking the price of the life-saving device, at the same time allegedly improperly classified the EpiPen as a generic drug. That led Medicaid and Medicare to both overpay for the product.
read more


Related Posts

EpiPen Maker Mylan Will Pay $465 Million to Settle Medicaid Overcharging Case

Business & Finance : DealBook

Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.

Mylan to pay $465M settlement over EpiPen

Business & Finance : USAToday: Money

EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices        

Mylan Agrees to Pay $465 Million for Ripping Off Medicare on EpiPens, Stock Price Soars

Technology / Gadgets : Gizmodo

Mylan, the drug company that makes EpiPen, has been overcharging Medicare and Medicaid for years. But today the pharmaceutical company had to finally pay the piper. In a deal announced by the notorious price-gougers, Mylan will hand...

Mylan to pay $465-million settlement over Medicaid EpiPen rebates

Business & Finance : LA Times: Business

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...

Mylan Surges After Quickly Settling With DoJ Over EpiPen Medicaid Rebates

Business & Finance / Personal Finance : Forbes: Personal Finance

Mylan will pay $465 million to settle with the Department of Justice over its classification of EpiPen in Medicaid rebate programs.


Copyright © 2016 Regator, LLC